drug · intermediate · partly written
Comirnaty (BNT162b2)
Comirnaty is a nucleoside-modified mRNA vaccine in lipid nanoparticles that encodes the SARS-CoV-2 spike protein; in the pivotal trial it prevented 95 percent of symptomatic cases.
Also called: BNT162b2, Pfizer-BioNTech COVID-19 vaccine
This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.
The short version
Comirnaty is a lipid-nanoparticle mRNA vaccine that makes cells produce the SARS-CoV-2 spike protein so the immune system learns it. In a trial of 43,548 people, 8 cases occurred in the vaccine group and 162 in the placebo group, a reported efficacy of 95 percent. 1
Reported, not yet replicated
How it works more
The mRNA is carried in tiny fat particles that stop it being broken down too quickly. After injection into a muscle, some cells read the mRNA and temporarily make the spike protein, the immune system recognises it as foreign and makes antibodies and T cell responses, and the mRNA is broken down shortly afterwards. The trial paper describes it as a lipid nanoparticle-formulated, nucleoside-modified RNA that encodes a prefusion-stabilised, membrane-anchored full-length spike. A review identifies the modification as N1-methyl-pseudouridine. 2314
Established
The decisive trial more
In a multinational, placebo-controlled, observer-blinded trial, 43,548 people aged 16 or older were randomised 1:1 to two doses 21 days apart of the vaccine candidate (30 micrograms per dose) or placebo. Counting cases with onset at least 7 days after the second dose, there were 8 cases among those given the vaccine and 162 among those given placebo: 95 percent efficacy (95 percent credible interval 90.3 to 97.6). Of 10 severe cases after the first dose, 9 were in placebo recipients. Similar efficacy, generally 90 to 100 percent, was seen across age, sex, race, ethnicity, body mass index and coexisting conditions. The EMA page gives the vaccine-group count as 8 of 18,198 people without prior infection. Only the abstract was opened. 12
Reported, not yet replicated
Regulatory path more
The European Commission granted a conditional marketing authorisation on 21 December 2020, converted to a standard authorisation on 10 October 2022. In the US the product page lists the biologics licence reference STN 125742 and BioNTech Manufacturing GmbH as manufacturer; the date of the first US approval letter was not established. 235
Established
Safety as reported deep
The trial abstract reports short-term, mild-to-moderate pain at the injection site, fatigue and headache, with serious adverse events low and similar in the vaccine and placebo groups over a median of 2 months. EMA later recommended adding myocarditis and pericarditis to the product information as side effects (28 July 2021 entry); the frequency was not read. 13
Reported, not yet replicated
Modality
Targets
Pathways
Indications
Identifiers
Code name
BNT162b2
Fda stn
125742
Trial
NCT04368728
Mechanism
Delivery route
Must survive
Side effects
Injection-site pain, fatigue, headache
Short-term, mild-to-moderate in the pivotal trial; counts per symptom were not in the abstract. 1
Reported, not yet replicated
Serious adverse events
Low in incidence and similar between vaccine and placebo groups over a median of 2 months. 1
Reported, not yet replicated
Myocarditis and pericarditis
Added to the product information as side effects after a 28 July 2021 EMA recommendation; frequency not read. 3
Reported, not yet replicated
Verdict
Outcome
worked
Teach this
In one sentence
Comirnaty is an mRNA vaccine in fat particles that makes the body briefly produce spike protein, and in the pivotal trial 8 vaccinated and 162 placebo recipients got symptomatic COVID-19. 12354
Reported, not yet replicated
The five-minute version
The vaccine is a modified mRNA recipe for the spike protein wrapped in lipid nanoparticles. Injected into the arm muscle, it is taken up by cells that briefly make spike, the immune system learns it, and the mRNA is broken down. In a trial of 43,548 people the vaccine group had 8 symptomatic cases and the placebo group 162. Short-lived injection-site pain, fatigue and headache were typical, and a later regulatory update added myocarditis and pericarditis. 12354
Reported, not yet replicated
What a listener will ask
Does the mRNA stay in the body?
EMA says it is broken down shortly after vaccination and that cells temporarily make the spike protein.
Why does it work better than CureVac CVnCoV?
Dose, RNA chemistry and variant era all differ and the trials did not isolate one; see the CVnCoV record.
Is 95 percent a guarantee?
The common wrong idea
An mRNA vaccine permanently alters a person.
The regulator describes the mRNA as broken down shortly after vaccination, with cells making spike only temporarily (EMA).
The one citation to hand over: 1
Still open here
- Full text of the pivotal trial and the EMA label were not opened; abstract and EMA overview pages were.
- Frequency of myocarditis and pericarditis was not read; the EMA page only records that they were added as side effects.
- The date of the first US approval letter was not established.
Not yet written: Assays used, Off targets.
Linked from
Sources
- Polack FP, Thomas SJ, Kitchin N, et al.. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383:2603-2615 (2020). paper; opened 2026-11-17 all records citing this
- European Medicines Agency. EMA recommends first COVID-19 vaccine for authorisation in the EU. EMA news page (2020). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- European Medicines Agency. Comirnaty: European public assessment report overview. EMA EPAR page (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Morais P, Adachi H, Yu YT. The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines. Front Cell Dev Biol 9:789427 (2021). review; opened 2026-11-17 all records citing this
- US Food and Drug Administration. COMIRNATY (COVID-19 Vaccine, mRNA). FDA CBER product page (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
History of this record (5)
This record has been changed 5 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Year
- 2020
- Regulatory status
- approved
- Status
- partly written
- Last updated
- 2026-11-19
- Record
- content/drugs/comirnaty.json